Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Would you consider anti-CD20 agents for treatment of multiple sclerosis in patients with history of breast cancer?
Related Questions
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What are the possible or expected MRI findings or changes in progressive MS?
How do you mitigate the risk of rebound disease activity when discontinuing S1p inhibitors or Tysabri in patients with multiple sclerosis?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
What is your treatment approach to neuropsychiatric symptoms secondary to lupus?
